Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02921776 · ClinicalTrials.gov registry record · NA
Vidatalk Communication Application: Usability, Acceptability and Efficacy Study
A NA study, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 147
- Enrollment target
NCT02921776 is a NA study that has completed, run by Ohio State University. The registered enrollment target is 147 participants.
The verdict
NCT02921776, a NA study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 147 participants
- Enrollment target
Study Summary
This Phase II Small Business Technology Transfer Research (STTR) will deliver a comprehensive patient communication solution for communication-impaired patients in the intensive care unit that may help decrease days in delirium, decrease anxiety levels, and reduce sedation exposure which are proximal outcomes known to be associated with decreased mechanical ventilation days, shorter lengths of ICU and hospital stay, and lower healthcare cost. The primary goal of this Phase II STTR proposal is to further define user requirements and product specifications and develop a prototype of VidaTalk, a patient-centric, touch pad communication software, to provide mechanically ventilated (MV) patients an evidence-based solution for effectively communicating their needs to care providers and family. A secondary goal is to test the impact of the VidaTalk on clinical outcomes. This study will use mixed methods including observations and interaction with hospitalized patients as they use the VidaTalk tool, surveys and medical record data extraction, product evaluation and brief interview, satisfaction surveys with family members of ICU patients, and focus groups with Registered Nurses. Specific Aim 1. Develop a commercial prototype of VidaTalk that will include multilingual and customizable messages, compatibility with tablet devices, picture symbols, and integration with mobile communication devices. Specific Aim 2. Demonstrate usability with iterative user assessment testing in a clinical setting. Specific Aim 3. Test the clinical efficacy of VidaTalk via android application with MV patients by examining qualitative and quantitative endpoints in a clinical setting. Aim 3 hypothesis: MV patients using VidaTalk will demonstrate significant reductions in patient-reported communication difficulty and frustration, anxiety, sedation exposure, delirium/coma-free days, and improved patient and family satisfaction with ICU care compared to MV patients receiving attention-control (i.e.
Interventions
- OTHER Aim 1 - VidaTalk - post-extubation
- OTHER Aim 2 - VidaTalk - intubated
- DEVICE Aim 3 - VidaTalk tablet app
- OTHER Aim 3 - attention-control with non-VidaTalk tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2018-02-19 |
| Est. Completion | 2019-06-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02921776
The ClinicalTrials.gov registry entry for NCT02921776 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Aim 1 - VidaTalk - post-extubation is the first listed.
NCT02921776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02921776 about?
NCT02921776 is a clinical study titled "Vidatalk Communication Application: Usability, Acceptability and Efficacy Study". This Phase II Small Business Technology Transfer Research (STTR) will deliver a comprehensive patient communication solution for communication-impaired patients in the intensive care unit that may help decrease days in delirium, decrease anxiety levels, and reduce sedation exposure which are proxima...
What is the current status of trial NCT02921776?
This trial is currently completed. It is a NA study. The enrollment target is 147 participants. The study started on 2018-02-19. Estimated completion is 2019-06-11.
What interventions are being tested in trial NCT02921776?
The interventions under investigation include: Aim 1 - VidaTalk - post-extubation (OTHER), Aim 2 - VidaTalk - intubated (OTHER), Aim 3 - VidaTalk tablet app (DEVICE), Aim 3 - attention-control with non-VidaTalk tablet (OTHER).
Who is sponsoring clinical trial NCT02921776?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.